Share price · ASND
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ASND's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Sep 2026-9.5%
- 31 Aug 2026+6.1%
- 25 Jun 2026+9.9%
Nothing announced by ASND that day or the session before.
- 29 May 2026-5.6%
Nothing announced by ASND that day or the session before.
- 22 Apr 2026-3.8%
- Day before6-K filing · 2 filings
Share of unusual movement by asset
For each asset, the share of ASND's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
palopegteriparatide (Yorvipath)events and moves
| 3 | shown from 8 days |
lonapegsomatropin (Skytrofa)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 45% |
| Sessions with no dated event | — | 55% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
lonapegsomatropin(Skytrofa) | Approved | Growth hormone receptorProtein / enzyme therapeutic | Growth Hormone Deficiency |
palopegteriparatide(Yorvipath) | Approved | PTH1 receptor (PTH replacement)Peptide | Hypoparathyroidism |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
August 2027 (1)
What to watch
2028 (2)
February 2028 (1)
What to watch
September 2028 (1)
What to watch
Financial reports
Quarterly & interim (13)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $250M | $78M | $633M | $71M$2.5M operating cash flow | report ↗ |
Ascendis Pharma Oncology Division A/S reported revenue of $249.65M, up 293.1% YoY, R&D spend of $78.16M, down 3.2% YoY, cash and equivalents of $632.51M, and a net loss of $71.27M for Q3 2025.
Figures only: this period's report disclosed no narrative text
View 12 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $179M | $82M | $579M | $44M-$8.3M operating cash flow | report ↗ |
| 2025-Q1 | $106M | $91M | $561M | $100M-$15M operating cash flow | report ↗ |
| 2024-Q3 | $64M | $81M | $699M | $109M-$62M operating cash flow | report ↗ |
| 2024-Q2 | $39M | $90M | $277M | $118M-$66M operating cash flow | report ↗ |
| 2024-Q1 | $104M | $77M | $346M | $142M-$110M operating cash flow | report ↗ |
| 2023-Q3 | $52M | $121M | $466M | $177M-$136M operating cash flow | report ↗ |
| 2023-Q2 | $52M | $114M | $428M | $132M-$167M operating cash flow | report ↗ |
| 2023-Q1 | $36M | $114M | $547M | $119M-$158M operating cash flow | report ↗ |
| 2022-Q3 | $15M | $98M | $598M | $170M-$100M operating cash flow | report ↗ |
| 2022-Q2 | $6.6M | $96M | $702M | $87M-$133M operating cash flow | report ↗ |
| 2022-Q1 | $7.7M | $93M | $843M | $141M-$147M operating cash flow | report ↗ |
| 2021-Q3 | $1.3M | $69M | $804M | $95M-$115M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $816M | $344M | $724M | $65M$61M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $394M | $332M | $582M | $102M-$331M operating cash flow | report ↗ |
| 2023-FY | $289M | $447M | $434M | $130M-$506M operating cash flow | report ↗ |
| 2022-FY | $54M | $400M | $474M | $154M-$522M operating cash flow | report ↗ |
| 2021-FY | $9.2M | $350M | $505M | $113M-$494M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 9 purchases ($777K), 4 sales ($10.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG · EVP & Chief Admin Officer | Option exercise | 20,000 | $37.18 | $744K | Form 4 |
| 2026-11-17 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG · EVP & Chief Admin Officer | Open-market sale | 20,000 | $263.89 | $5.3M | Form 4 |
| 2026-11-17 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG · EVP & Chief Admin Officer | Option exercise (derivative) | 20,000 | — | — | Form 4 |
| 2026-09-08 | Bodenhoff Mads · SVP & PAO | Option exercise | 3,000 | $110.00 | $330K | Form 4 |
| 2026-09-08 | Bodenhoff Mads · SVP & PAO | Open-market sale | 3,000 | $270.19 | $811K | Form 4 |
| 2026-09-08 | Bodenhoff Mads · SVP & PAO | Option exercise (derivative) | 3,000 | — | — | Form 4 |
| 2026-09-02 | HOLTUG LARS · director | Open-market sale | 236 | $264.13 | $62K | Form 4 |
| 2026-08-14 | BIENAIME JEAN JACQUES · director | Open-market purchase | 1,100 | $245.85 | $270K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 7.9M shares ($34.4M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Driehaus Capital Management LLC | 127,562 | $29.2M |
| 2 | Evolutionary Tree Capital Management, LLC | 9,070 | $2.1M |
| 3 | T. Rowe Price Investment Management, Inc. | 6,162,042 | $1.4M |
| 4 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 5,784 | $1.3M |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 1,530,345 | $350K |
| 6 | Q Global Advisors, LLC | 100,000 | $23K |
| 7 | SBI Securities Co., Ltd. | 3 | $686 |